AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BLACKSTONE MINERALS LTD

0.044

+0.0037.32%

Volume:959.77K

Turnover:43.16K

Market Cap:75.65M

PE:-3.52

High:0.048

Open:0.046

Low:0.044

Close:0.041

52wk High:0.086

52wk Low:0.028

Shares:1.72B

Float Shares:1.38B

Volume Ratio:20.70

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.013

EPS(LYR):-0.016

ROE:-28.74%

ROA:-16.85%

PB:0.82

PE(LYR):-2.72

Loading ...

Overview Company News Filings

Boston Scientific (BSX) Valuation After Downgrade Litigation And Concerns Over Slower Growth

Simply Wall St.

Do Boston Scientific’s (BSX) WATCHMAN Win and Asurys Launch Quietly Recast Its Long-Term Growth Story?

Simply Wall St.

Boston Scientific's 2026 Guidance 'Reasonable', RBC Says

MT Newswires Live

Top Midday Stories: Trump Touts Talks With New Iranian Regime, Renews Threats; Sysco to Acquire Jetro for $29.1 Billion

MT Newswires Live

Boston Scientific Posts Positive Trial Data For Ekos Blood Clot Device

MT Newswires Live

Boston Scientific Says Stroke Risk Reduction Device Trial Meets All Endpoints

MT Newswires Live

Boston Scientific (BSX) Valuation Check As Electrophysiology Concerns And Lawsuit Weigh On Sentiment

Simply Wall St.

Boston Scientific's CHAMPION-AF Trial in Focus, Oppenheimer Says

MT Newswires Live

Here's Why We're Watching Blackstone Minerals' (ASX:BSX) Cash Burn Situation

Simply Wall St.

Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million

MT Newswires Live

BRIEF-Blackstone Minerals Posts Loss Attributable Of A$10.9 Million For Half-Year

Abbott Laboratories' Structural Heart Business Could See Upside From Watchman Trial Results, UBS Says

MT Newswires Live

Boston Scientific Corp Stock Moved Down by 3.32% on Mar 3: Facts Behind the Movement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BSX.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","market":"AU","secType":"STK","nameCN":"BLACKSTONE MINERALS LTD","latestPrice":0.044,"timestamp":1788223108755,"preClose":0.041,"halted":0,"volume":959767,"delay":0,"changeRate":0.07317073170731697,"nameEN":"BLACKSTONE MINERALS LTD","floatShares":1378369438,"shares":1719359861,"eps":-0.012512,"marketStatus":"Trading","change":0.003,"latestTime":"09-01 10:45:53 AEST","open":0.046,"high":0.048,"low":0.044,"amount":43160,"amplitude":0.097561,"askPrice":0.045,"askSize":258164,"bidPrice":0.044,"bidSize":1190,"shortable":3,"etf":0,"ttmEps":-0.012512,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788242400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.041,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":20.704409,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BSX.AU","preClose":0.039,"auctionPrice":0.039,"auctionVolume":385214,"auction":3,"marketStatus":"盘后竞价","timestamp":1787551242943}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","floatShares":1378369438,"roa":"-16.85%","roe":"-28.74%","lyrEps":-0.01616,"volumeRatio":20.704409,"shares":1719359861,"dividePrice":0,"high":0.048,"amplitude":0.097561,"preClose":0.041,"low":0.044,"week52Low":0.028,"pbRate":"0.82","psRate":"-77.10","week52High":0.086,"institutionHeld":0,"latestPrice":0.044,"committee":-0.990823,"eps":-0.012512,"divideRate":0,"volume":959767,"delay":0,"ttmEps":-0.012512,"open":0.046,"prevYearClose":0.055,"prevWeekClose":0.044,"prevMonthClose":0.041,"prevQuarterClose":0.033,"fiveDayClose":0.04,"twentyDayClose":0.041,"sixtyDayClose":0.043},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSX.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625628148","title":"Boston Scientific (BSX) Valuation After Downgrade Litigation And Concerns Over Slower Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2625628148","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625628148?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:10","pubTimestamp":1775419840,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) is under pressure after a sharp sentiment swing, driven by an analyst downgrade tied to slower expectations in U.S. electrophysiology and Watchman, softer guidance, and a series of securities class action filings.\nSee our latest analysis for Boston Scientific.\nDespite a series of positive trial readouts and new product clearances in recent weeks, sentiment has turned sharply, with a 34.21% 3 month share price decline and a 29.97% 1 year total shareholder return leaving...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-valuation-after-downgrade-litigation-a","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-valuation-after-downgrade-litigation-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BSX.AU","BSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624684241","title":"Do Boston Scientific’s (BSX) WATCHMAN Win and Asurys Launch Quietly Recast Its Long-Term Growth Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624684241","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624684241?lang=en_us&edition=fundamental","pubTime":"2026-04-03 02:39","pubTimestamp":1775155143,"startTime":"0","endTime":"0","summary":"In late March 2026, Boston Scientific announced landmark CHAMPION-AF trial results showing its WATCHMAN FLX left atrial appendage closure device matched non-vitamin K antagonist oral anticoagulants on stroke prevention while reducing clinically relevant bleeding, alongside FDA 510(k) clearance for the Asurys Fluid Management System for endoscopic urologic procedures.\nThe unusual combination of clinically strong WATCHMAN data and a new kidney-stone-focused irrigation platform with intrarenal...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/do-boston-scientifics-bsx-watchman-win-and-asurys-launch-qui","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BSX.AU","BK4588","LU0011850046.USD","LU1804176565.USD","LU1791710582.SGD","LU1989764664.SGD","LU2087625088.SGD","LU0267386448.USD","BK4581","LU0077335932.USD","LU0432979614.USD","LU2506951875.HKD","IE00BJJMRZ35.SGD","LU0138981039.USD","LU0187121727.USD","LU0823417653.USD","LU2491049909.HKD","LU2491050154.USD","LU0823416689.USD","LU2324357040.USD","LU1061106388.HKD","IE0009355771.USD","LU0345769631.USD","LU1989772923.USD","LU2362541273.HKD","LU2506951958.HKD","SG9999001176.SGD","LU0048584097.USD","LU1718418525.SGD","LU0528227936.USD","LU2242649171.HKD","LU1057294990.SGD","LU0114720955.EUR","LU2357305700.SGD","LU1023059063.AUD","LU0353189763.USD","LU0950375773.USD","BK4082","LU2265009873.SGD","SG9999013999.USD","LU2244417387.USD","LU2506952097.USD","IE00BFTCPJ56.SGD","LU0251132253.USD","LU0823417737.USD","LU1989772840.SGD","LU1366192091.USD","BSX","LU0225283273.USD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500614","title":"Boston Scientific's 2026 Guidance 'Reasonable', RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500614","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624500614?lang=en_us&edition=fundamental","pubTime":"2026-04-02 22:57","pubTimestamp":1775141852,"startTime":"0","endTime":"0","summary":"Boston Scientific's  2026 guidance is \"reasonable\", but stock sentiment is being driven by the Q1 performance of its Pulsed Field Ablation and Left Atrial Appendage Closure System products, RBC Capital Markets analysts said in a Thursday note.Analysts said that the company's 2026 guidance factors in growth contributions of about 250 basis points from Electrophysiology, 200 basis points from Watchman, and the remaining 550 basis points from the base business.RBC said that \"cadence through the year, including for Q1, can be choppy and remains in high focus among investors with most cautious ahead of the print.\"Analysts said that the company has multiple growth drivers across its businesses, including its renal denervation business, intravascular lithotripsy, and the Penumbra acquisition, among others.RBC said that Boston Scientific's stock is trading at its 5-year lows, failing to fully reflect its growth profile and financial strength.Analysts have an outperform rating on the stock and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0077335932.USD","LU1989771016.USD","LU0823417653.USD","BK7095","LU1720051108.HKD","IE0009355771.USD","LU2506951958.HKD","LU0225283273.USD","LU0345769631.USD","LU2244417387.USD","LU1989764748.USD","LU2491050154.USD","LU0266013472.USD","LU1804176565.USD","BSX.AU","LU1983299246.USD","LU0882574055.USD","LU2265009873.SGD","LU1023059063.AUD","LU2087625088.SGD","IE00B4R5TH58.HKD","LU0823416689.USD","LU1061106388.HKD","LU2506952170.USD","LU1989772840.SGD","LU1366192091.USD","SG9999001176.SGD","LU0251132253.USD","BK4588","BSX","LU2362540622.SGD","LU0114720955.EUR","LU0138981039.USD","LU0950375773.USD","LU0353189763.USD","LU0528227936.USD","LU1548497426.USD","LU0048584097.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU2506952097.USD","LU1989772923.USD","SG9999001176.USD","LU1153585028.USD","LU0238689110.USD","LU0187121727.USD","LU2506951875.HKD","LU0011850046.USD","LU1720051017.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623449663","title":"Top Midday Stories: Trump Touts Talks With New Iranian Regime, Renews Threats; Sysco to Acquire Jetro for $29.1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2623449663","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623449663?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:27","pubTimestamp":1774884469,"startTime":"0","endTime":"0","summary":"All three major US stock indexes were up in late-morning trading Monday after President Donald Trump said in a Truth Social post that the US is working with the new regime in Iran to end the military ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2244417387.USD","LU0238689110.USD","LU2211817866.USD","UTHR","BK4504","LU0345769128.USD","LU1989772923.USD","LU2242649171.HKD","LU1720051108.HKD","LU0114720955.EUR","LU2362541273.HKD","LU0048584097.USD","IE00B4R5TH58.HKD","LU1989771016.USD","LU1791710582.SGD","VRDN","LU0477156797.USD","LU2362541513.USD","LU2362540622.SGD","LU1989772840.SGD","BK4585","LU1718418525.SGD","LU0266013472.USD","LU1061106388.HKD","SG9999001176.SGD","LU2087625088.SGD","LU1057294990.SGD","LU0950375773.USD","LU1720051017.SGD","LU2112291526.USD","LU0353189763.USD","LU1291159041.SGD","BSX.AU","LU0251132253.USD","LU0823416689.USD","BK4588","LU1989763427.SGD","LU2506951875.HKD","BK4532","SG9999001176.USD","LU2506951958.HKD","LU0648000940.SGD","IE0002141913.USD","LU0077335932.USD","SYY","LU2491050071.SGD","LU0011850046.USD","IE0009355771.USD","LU1989764664.SGD","BSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623319841","title":"Boston Scientific Posts Positive Trial Data For Ekos Blood Clot Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2623319841","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623319841?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:33","pubTimestamp":1774866788,"startTime":"0","endTime":"0","summary":"Boston Scientific  said Saturday that a global clinical trial demonstrated its Ekos blood clot device, combined with anticoagulants, outperformed standard treatments for patients with intermediate-risk pulmonary embolisms.The study met its primary endpoint by reducing associated mortality and severe respiratory failure events by 61% within seven days compared to using blood thinners alone, the company said.Patients treated with the targeted ultrasound system experienced a 4% overall complication rate versus 10.3% in the control group without any instances of brain bleeding over 30 days, Boston Scientific said.The research enrolled 544 participants from both the US and Europe, with patient monitoring scheduled to continue for one year following the procedure, it added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0353189763.USD","LU1989772923.USD","LU0251132253.USD","LU1548497426.USD","LU1989764664.SGD","LU2112291526.USD","LU2265009873.SGD","LU1061106388.HKD","LU1057294990.SGD","IE00B2B36J28.USD","LU2087625088.SGD","LU0950375773.USD","LU2491049909.HKD","BK4082","LU1720051017.SGD","IE0009355771.USD","LU0238689110.USD","LU1989764748.USD","LU0077335932.USD","LU0528227936.USD","LU2362541273.HKD","SGXZ57979304.SGD","LU2362541513.USD","BSX.AU","LU2506951958.HKD","BSX","LU2491050154.USD","LU0011850046.USD","LU2362540622.SGD","LU1718418525.SGD","IE0002141913.USD","LU0267386448.USD","LU1989772840.SGD","SG9999001176.USD","LU1291159041.SGD","LU2357305700.SGD","LU2324357040.USD","SG9999013999.USD","LU0432979614.USD","BK4504","LU0187121727.USD","LU0266013472.USD","LU0353189680.USD","LU1791710400.SGD","LU1023059063.AUD","BK7095","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623988316","title":"Boston Scientific Says Stroke Risk Reduction Device Trial Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2623988316","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623988316?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:17","pubTimestamp":1774865838,"startTime":"0","endTime":"0","summary":"Boston Scientific  said Saturday a trial of the Watchman FLX left atrial appendage closure device met all its primary and secondary safety and efficacy endpoints.The study evaluated the device versus non-vitamin K antagonist oral anticoagulants as a first-line option for stroke risk reduction in patients with non-valvular atrial fibrillation, a heart rhythm disorder.Results showed that the device provided \"statistically superior\" protection from bleeding and demonstrated similar efficacy compared with blood thinners, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2362541273.HKD","BSX","LU2506951958.HKD","LU1023059063.AUD","BK4588","LU0225283273.USD","LU0011850046.USD","LU0114720955.EUR","LU2242649171.HKD","LU2244417387.USD","LU0345769128.USD","LU2357305700.SGD","LU0266013472.USD","LU1061106388.HKD","LU2362541513.USD","BSX.AU","LU0345769631.USD","LU2087625088.SGD","LU1153585028.USD","LU1989764748.USD","LU2265009873.SGD","BK4082","LU1718418525.SGD","SG9999001176.SGD","LU2491050154.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1057294990.SGD","LU0823417737.USD","IE0009355771.USD","LU0238689110.USD","LU2362540622.SGD","LU1989772923.USD","IE00BJT1NW94.SGD","LU1720051017.SGD","LU1804176565.USD","LU1989771016.USD","LU0353189680.USD","LU0122379950.USD","LU2112291526.USD","LU0353189763.USD","LU1291159041.SGD","LU0823416689.USD","LU1720051108.HKD","SG9999001176.USD","LU0528227936.USD","LU2506952097.USD","LU0267386448.USD","LU0823417653.USD","LU0251132253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622823424","title":"Boston Scientific (BSX) Valuation Check As Electrophysiology Concerns And Lawsuit Weigh On Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2622823424","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622823424?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:04","pubTimestamp":1774609482,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) stock has come under pressure after a class action lawsuit accused the company of misleading investors about its Electrophysiology growth prospects, following cautious 2026 guidance and a sharp post-earnings share price drop.\nSee our latest analysis for Boston Scientific.\nAt a share price of US$70.17, Boston Scientific has seen a 1-day share price return of 0.56% and a 7-day share price return of 0.40%. However, the 30-day and 90-day share price returns of 6.63% and...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-valuation-check-as-electrophysiology-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-valuation-check-as-electrophysiology-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0266013472.USD","IE00BJT1NW94.SGD","LU2491050071.SGD","LU0950375773.USD","LU2242649171.HKD","LU0345769631.USD","LU0432979614.USD","LU0353189763.USD","LU1720051017.SGD","SG9999013999.USD","IE00B4R5TH58.HKD","BK4504","IE0002141913.USD","LU1989771016.USD","LU2362540622.SGD","BK4082","LU0225283273.USD","LU1791710400.SGD","LU0882574055.USD","LU1983299246.USD","LU2506952170.USD","LU0353189680.USD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU2087625088.SGD","LU0187121727.USD","BSX","IE00BJJMRZ35.SGD","SG9999001176.SGD","LU1804176565.USD","BSX.AU","LU0114720955.EUR","LU2265009873.SGD","LU0238689110.USD","LU1989772840.SGD","LU2324357040.USD","LU2491049909.HKD","LU0048584097.USD","LU2112291526.USD","LU1720051108.HKD","LU0011850046.USD","LU1989772923.USD","LU1291159041.SGD","LU2491050154.USD","BK4585","SG9999001176.USD","LU0122379950.USD","LU2506951958.HKD","LU0823417653.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622864860","title":"Boston Scientific's CHAMPION-AF Trial in Focus, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2622864860","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622864860?lang=en_us&edition=fundamental","pubTime":"2026-03-26 23:24","pubTimestamp":1774538652,"startTime":"0","endTime":"0","summary":"Boston Scientific's  CHAMPION-AF trial of its heart implant device to lower stroke risk is among the most anticipated study readouts this year, Oppenheimer said in a note Thursday.\"To be clear, consensus view is that the trial will be successful, both technically & clinically,\" the report said.The clinical trial is evaluating left atrial appendage closure versus non-vitamin K antagonist oral anticoagulants in a broad non-valvular atrial fibrillation patient population to establish Watchman FLX as a first-line stroke risk-reduction therapy.The report said how the trial data stacks up will be critical in expanding the total addressable market.\"In our view, the data has to withstand the \"clinical success\" criteria for true TAM expansion,\" the report said.Oppenheimer has an outperform rating with a $100 price target.Price: 70.55, Change: +0.77, Percent Change: +1.10","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2244417387.USD","LU1366192091.USD","LU2265009873.SGD","LU2324357040.USD","LU1548497426.USD","LU0122379950.USD","LU0345769128.USD","LU0882574055.USD","LU1720051108.HKD","LU0114720955.EUR","LU0048584097.USD","IE00B4R5TH58.HKD","BK4581","IE00BFTCPJ56.SGD","OPY","SG9999013999.USD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","LU1983299246.USD","LU0267386448.USD","LU2357305700.SGD","LU1989772840.SGD","BK4127","BK4585","LU0266013472.USD","LU1061106388.HKD","SG9999001176.SGD","LU2087625088.SGD","LU0823417737.USD","LU2112291526.USD","BK7095","LU0353189763.USD","BSX.AU","LU1291159041.SGD","LU0823416689.USD","BK4588","LU2506952170.USD","LU0823417653.USD","IE00B2B36J28.USD","LU2506951958.HKD","LU0187121727.USD","SG9999001176.USD","LU1153585028.USD","IE00BJJMRZ35.SGD","LU0353189680.USD","LU2506952097.USD","LU0011850046.USD","IE0009355771.USD","LU1989764664.SGD","BSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622883140","title":"Here's Why We're Watching Blackstone Minerals' (ASX:BSX) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883140","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883140?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:01","pubTimestamp":1774472474,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-bsx/blackstone-minerals-shares/news/heres-why-were-watching-blackstone-minerals-asxbsx-cash-burn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-bsx/blackstone-minerals-shares/news/heres-why-were-watching-blackstone-minerals-asxbsx-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2506952097.USD","IE00B4R5TH58.HKD","LU2362540622.SGD","LU2491050071.SGD","BK7095","LU0528227936.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU1720051108.HKD","BK4504","BK4082","LU2087625088.SGD","LU2244417387.USD","LU0225283273.USD","LU2506951875.HKD","LU0238689110.USD","LU1989772840.SGD","LU0432979614.USD","IE0002141913.USD","LU2506951958.HKD","BK4588","LU2242649171.HKD","BSX.AU","LU1548497426.USD","LU1791710582.SGD","LU1804176565.USD","LU2357305700.SGD","LU0823416689.USD","LU0882574055.USD","LU1791710400.SGD","BSX","LU2491050154.USD","LU1983299246.USD","LU0950375773.USD","LU1989771016.USD","SG9999013999.USD","LU1989764664.SGD","LU0823417653.USD","LU0353189680.USD","SG9999001176.USD","LU1153585028.USD","LU1718418525.SGD","LU2362541273.HKD","LU0345769128.USD","LU0267386448.USD","IE00BJT1NW94.SGD","LU0048584097.USD","LU1989772923.USD","LU0353189763.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620927581","title":"Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620927581","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620927581?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:04","pubTimestamp":1773947053,"startTime":"0","endTime":"0","summary":"Boston Scientific  amended the recall of its Accolade pacemakers again, updating the software further and expanding the affected population to 1.6 million people, the New York Times reported Thursday, citing company documents and filings.The latest recall includes newer devices including \"dual chamber\" pacemakers and \"cardiac resynchronization\" pacemakers. Boston Scientific said these devices have a 7.6% chance of needing early replacement because they might encounter a high impedance battery issue at some point, The New York Times added.The company said the software update effectively mitigates the risk of Safety Mode, but patients must visit their doctors to benefit from the update, according to the report.Boston Scientific did not immediately respond to a request for comment by MT Newswires.Price: 70.39, Change: -0.89, Percent Change: -1.25","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1153585028.USD","IE00B2B36J28.USD","LU0238689110.USD","IE0002141913.USD","LU1023059063.AUD","LU2506951875.HKD","LU0187121727.USD","LU0528227936.USD","LU1989764664.SGD","LU2265009873.SGD","BK4588","LU1989764748.USD","LU0345769128.USD","IE00BJT1NW94.SGD","LU0353189680.USD","BSX.AU","LU0882574055.USD","BK4504","LU2357305700.SGD","LU1366192091.USD","LU1804176565.USD","LU2506951958.HKD","LU0122379950.USD","LU0345769631.USD","LU0353189763.USD","LU0823416689.USD","SGXZ57979304.SGD","LU0251132253.USD","LU0266013472.USD","ACCD","LU2362540622.SGD","LU1548497426.USD","LU0114720955.EUR","LU1057294990.SGD","LU1061106388.HKD","LU2491049909.HKD","LU0225283273.USD","SG9999001176.SGD","LU1791710400.SGD","LU1720051017.SGD","BK4581","LU2491050154.USD","BSX","LU2242649171.HKD","LU1291159041.SGD","LU2362541273.HKD","LU2491050071.SGD","LU0823417737.USD","BK4585","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619245121","title":"BRIEF-Blackstone Minerals Posts Loss Attributable Of A$10.9 Million For Half-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245121","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619245121?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:26","pubTimestamp":1773656819,"startTime":"0","endTime":"0","summary":"BRIEF-Blackstone Minerals Posts Loss Attributable Of A$10.9 Million For Half-Year March 16 (Reuters) - Blackstone Minerals Ltd BSX.AX:LOSS FOR HALF-YEAR ATTRIBUTABLE A$10.9 MILLIONFurther company coverage: BSX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40301W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX.AU","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619086116","title":"Abbott Laboratories' Structural Heart Business Could See Upside From Watchman Trial Results, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2619086116","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619086116?lang=en_us&edition=fundamental","pubTime":"2026-03-13 23:33","pubTimestamp":1773416003,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  structural heart business could see \"meaningful upside\" from readout of positive results of Boston Scientific's  clinical trial of the Watchman implant at the end of March, UBS said in a note emailed Friday.Positive trial results could spark a broader growth in the structural heart area that could indirectly lift Abbott's MedTech segment through a modest market capture, UBS analysts said. Their scenario analysis suggests that even small market share gains have the potential to raise the MedTech segment's five-year compound annual growth rate to sustainable double-digit growth levels, compared to the consensus of 9.6% over the 2025-2030 period.Although the company's shares have been down 11% year-to-date from 52-week highs partly due to investors' concerns about deceleration in key growth areas within the MedTech segment, the analysts said they believe that the structural heart division remains \"underappreciated.\"UBS reiterated the company's stock rating at buy and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0234572021.USD","BSX.AU","LU1989772923.USD","LU2324357040.USD","BK4588","IE0009355771.USD","LU2491050154.USD","LU0225283273.USD","LU2362541513.USD","LU1721429402.USD","LU1718418525.SGD","BK4581","LU2211815571.USD","IE00BJT1NW94.SGD","BK4504","SG9999002224.SGD","LU0345769128.USD","LU1983299246.USD","LU0823416689.USD","BK4592","LU1914381329.SGD","LU0122379950.USD","LU2133065610.SGD","ABT","LU0882574055.USD","LU0432979614.USD","LU0266013472.USD","LU0058720904.USD","LU1691799644.USD","LU1720051017.SGD","SG9999001176.USD","LU2237957811.SGD","LU0187121727.USD","LU2491049909.HKD","LU1061106388.HKD","LU2357305700.SGD","BSX","ABT.AU","IE00BJJMRZ35.SGD","LU1804176565.USD","LU1989763427.SGD","LU0353189680.USD","LU0048584097.USD","LU2244417387.USD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU1989772840.SGD","BK4585","LU1023059063.AUD","LU0011850046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616378835","title":"Boston Scientific Corp Stock Moved Down by 3.32% on Mar 3: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616378835","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616378835?lang=en_us&edition=fundamental","pubTime":"2026-03-04 01:15","pubTimestamp":1772558137,"startTime":"0","endTime":"0","summary":"• Boston Scientific faces recall of AXIOS Stent, triggering investigations.\n• $14.5 billion Penumbra acquisition adds debt and dilutes earnings.\n• Electrophysiology segment underperformed; sales guidance lowered.","market":"us","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261640854-market-movers-bsx-20260303","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX.AU","BK4588","LU0011850046.USD","LU1989764664.SGD","LU1791710582.SGD","LU1989771016.USD","SEM","BK7095","LU2087625088.SGD","LU0345769128.USD","BK4581","LU1791710400.SGD","IE0002141913.USD","LU0077335932.USD","LU1291159041.SGD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU0823417653.USD","NMTC","LU2506952170.USD","LU0353189680.USD","LU2491050154.USD","LU0345769631.USD","LU1989772923.USD","LU2362541273.HKD","LU2506951958.HKD","SG9999001176.SGD","LU0528227936.USD","LU2242649171.HKD","LU0114720955.EUR","LU2357305700.SGD","ZJYL","LU0353189763.USD","LU0950375773.USD","LU0266013472.USD","BK4585","BK4082","LU2362540622.SGD","LU1989764748.USD","LU2112291526.USD","LU2244417387.USD","LU0122379950.USD","LU2506952097.USD","SG9999013999.USD","LU1153585028.USD","LU0823417737.USD","IE00B4R5TH58.HKD","BSX","LU0225283273.USD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":53,"code":"91000000","status":"200"}]}}